eTable 3. Medications taken on a regular basis (for at least 12 months).
| Total study population | p-value*1 | Post-COVID-19 (Symptom duration ≥ 12 weeks) | p-value*1 | |||
| No symptoms/ symptoms < 12 weeks n = 739 | Symptoms ≥ 12 weeks(post-COVID-19) n = 720 | Not hospitalized n = 588 | Hospitalized n = 127 | |||
| ACE-I and ARB | 108 (14.6) | 172 (23.9) | < 0.001 | 108 (18.4) | 63 (49.6) | < 0.001 |
| Other antihypertensives | 118 (16.0) | 159 (22.1) | 0.011 | 98 (16.7) | 61 (48.0) | < 0.001 |
| Metformin | 20 (2.7) | 40 (5.6) | 0.008 | 21 (3.6) | 19 (15.0) | < 0.001 |
| Other antidiabetics | 18 (2.4) | 30 (4.2) | 0.077 | 16 (2.7) | 14 (11.0) | < 0.001 |
| Diuretics | 51 (6.9) | 79 (11.0) | 0.023 | 39 (6.5) | 41 (32.3) | < 0.001 |
| Lung inhalers | 33 (4.5) | 71 (9.9) | < 0.001 | 47 (8.0) | 22 (17.3) | < 0.001 |
| Cholesterol-reducing drugs | 53 (7.2) | 90 (12.5) | 0.002 | 53 (9.0) | 37 (29.1) | < 0.001 |
| ASA 100 | 51 (6.9) | 83 (11.5) | 0.006 | 49 (8.3) | 33 (26.0) | < 0.001 |
| Anticoagulants | 36 (4.9) | 44 (6.1) | 0.584 | 16 (2.7) | 28 (22.0) | < 0.001 |
| Opiates and morphines | 11 (1.5) | 16 (2.2) | 0.498 | 9 (1.5) | 7 (5.5) | < 0.001 |
| Other analgesics | 59 (8.0) | 83 (11.5) | 0.041 | 58 (9.9) | 25 (19.7) | < 0.001 |
| Vitamin D | 104 (14.1) | 157 (21.8) | < 0.001 | 118 (20.1) | 38 (29.9) | 0.018 |
| Antidepressants*3 | 12 (1.6) | 38 (5.3) | < 0.001 | 28 (4.8) | 10 (7.9) | 0.156 |
| Thyroid medications*3 | 68 (9.2) | 119 (15.3) | < 0.001 | 93 (15.8) | 16 (12.6) | 0.360 |
| Homeopathic preparations*3 | 7 (0.9) | 19 (2.6) | 0.015 | 14 (2.4) | 5 (3.9) | 0.323 |
| Proton pump inhibitors*3 | 15 (2.0) | 25 (3.5) | 0.092 | 20 (3.4) | 5 (3.9) | 0.766 |
| Contraceptives*3 | 16 (2.2) | 21 (2.9) | 0.407 | 20 (3.4) | 1 (0.8) | 0.149*2 |
| Vitamins and supplements*3 | 26 (3.5) | 35 (4.9) | 0.200 | 27 (4.6) | 8 (6.3) | 0.419 |
| Other medications*3 | 57 (7.7) | 86 (11.9) | 0.007 | 59 (10.0) | 27 (21.3) | < 0.001 |
Absolute and relative frequencies are presented as n (%). Information on hospitalization was missing for five patients in the post-COVID-19 group.
ACE-I, Angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; ASA 100, acetylsalicylic acid 100 milligram
*1 Chi-square tests were used to calculate p-values unless otherwise indicated. *2 Fisher’s exact test. *3 Information from the optional text boxes